These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 29067878)
1. Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET. Collier TL; Maresca KP; Normandin MD; Richardson P; McCarthy TJ; Liang SH; Waterhouse RN; Vasdev N Mol Imaging; 2017; 16():1536012117736669. PubMed ID: 29067878 [TBL] [Abstract][Full Text] [Related]
2. First macrocyclic 3 Basit S; Ashraf Z; Lee K; Latif M Eur J Med Chem; 2017 Jul; 134():348-356. PubMed ID: 28431340 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and preliminary PET imaging of Collier TL; Normandin MD; Stephenson NA; Livni E; Liang SH; Wooten DW; Esfahani SA; Stabin MG; Mahmood U; Chen J; Wang W; Maresca K; Waterhouse RN; El Fakhri G; Richardson P; Vasdev N Nat Commun; 2017 Jun; 8():15761. PubMed ID: 28594000 [TBL] [Abstract][Full Text] [Related]
4. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098 [TBL] [Abstract][Full Text] [Related]
5. Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib. Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH Eur J Pharm Biopharm; 2019 Mar; 136():120-130. PubMed ID: 30660696 [TBL] [Abstract][Full Text] [Related]
6. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. Johnson TW; Richardson PF; Bailey S; Brooun A; Burke BJ; Collins MR; Cui JJ; Deal JG; Deng YL; Dinh D; Engstrom LD; He M; Hoffman J; Hoffman RL; Huang Q; Kania RS; Kath JC; Lam H; Lam JL; Le PT; Lingardo L; Liu W; McTigue M; Palmer CL; Sach NW; Smeal T; Smith GL; Stewart AE; Timofeevski S; Zhu H; Zhu J; Zou HY; Edwards MP J Med Chem; 2014 Jun; 57(11):4720-44. PubMed ID: 24819116 [TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib. Li W; Sparidans RW; Wang Y; Lebre MC; Wagenaar E; Beijnen JH; Schinkel AH Int J Cancer; 2018 Oct; 143(8):2029-2038. PubMed ID: 29744867 [TBL] [Abstract][Full Text] [Related]
8. Lorlatinib for the treatment of patients with non-small cell lung cancer. Akamine T; Toyokawa G; Tagawa T; Yamazaki K; Seto T; Takeo S; Mori M Drugs Today (Barc); 2019 Feb; 55(2):107-116. PubMed ID: 30816885 [TBL] [Abstract][Full Text] [Related]
9. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Zou HY; Li Q; Engstrom LD; West M; Appleman V; Wong KA; McTigue M; Deng YL; Liu W; Brooun A; Timofeevski S; McDonnell SR; Jiang P; Falk MD; Lappin PB; Affolter T; Nichols T; Hu W; Lam J; Johnson TW; Smeal T; Charest A; Fantin VR Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3493-8. PubMed ID: 25733882 [TBL] [Abstract][Full Text] [Related]
10. Molecular Simulation Studies on the Binding Selectivity of Type-I Inhibitors in the Complexes with ROS1 versus ALK. Tian Y; Yu Y; Shen Y; Wan H; Chang S; Zhang T; Wan S; Zhang J J Chem Inf Model; 2017 Apr; 57(4):977-987. PubMed ID: 28318251 [TBL] [Abstract][Full Text] [Related]
11. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers. Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242 [TBL] [Abstract][Full Text] [Related]
12. Lorlatinib: First Global Approval. Syed YY Drugs; 2019 Jan; 79(1):93-98. PubMed ID: 30604291 [TBL] [Abstract][Full Text] [Related]
13. Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1. Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P J Pharmacol Exp Ther; 2014 Oct; 351(1):67-76. PubMed ID: 25073473 [TBL] [Abstract][Full Text] [Related]
14. Lorlatinib Is Active in Drug-Resistant NSCLC. Cancer Discov; 2016 Aug; 6(8):OF1. PubMed ID: 27401797 [TBL] [Abstract][Full Text] [Related]
15. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. Roskoski R Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216 [TBL] [Abstract][Full Text] [Related]
16. Conformational Studies and Atropisomerism Kinetics of the ALK Clinical Candidate Lorlatinib (PF-06463922) and Desmethyl Congeners. Elleraas J; Ewanicki J; Johnson TW; Sach NW; Collins MR; Richardson PF Angew Chem Int Ed Engl; 2016 Mar; 55(11):3590-5. PubMed ID: 26880581 [TBL] [Abstract][Full Text] [Related]
17. Dual potent ALK and ROS1 inhibitors combating drug-resistant mutants: Synthesis and biological evaluation of aminopyridine-containing diarylaminopyrimidine derivatives. Guo M; Zuo D; Zhang J; Xing L; Gou W; Jiang F; Jiang N; Zhang D; Zhai X Eur J Med Chem; 2018 Oct; 158():322-333. PubMed ID: 30223120 [TBL] [Abstract][Full Text] [Related]
18. Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. Wang Y; Chen S; Hu G; Wang J; Gou W; Zuo D; Gu Y; Gong P; Zhai X Eur J Med Chem; 2018 Jan; 143():123-136. PubMed ID: 29174809 [TBL] [Abstract][Full Text] [Related]
19. A user's guide to lorlatinib. Nagasaka M; Ge Y; Sukari A; Kukreja G; Ou SI Crit Rev Oncol Hematol; 2020 Jul; 151():102969. PubMed ID: 32416346 [TBL] [Abstract][Full Text] [Related]